NRIX vs PFE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PFE is the larger of the two ($156.92B market cap): the incumbent the market prices for continued execution (9.32x forward earnings, beta 0.30). NRIX is the smaller challenger ($1.43B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, NRIX fits (beta 1.78). If you want the steadier ride, PFE fits (beta 0.3).

NRIX vs PFE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNRIXPFEWhat it tells you
Market cap$1.43B$156.92BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-10.249.32Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E5.3839.33Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.780.30Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range0% of range50% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.471.76How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how NRIX and PFE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NRIX and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NRIX and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Nurix Therapeutics (NRIX) do?

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a registrational Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study, comparing it with pirtobrutinib in about 620 patients, that enrolled its first patient by October 2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

Full NRIX guide

What does Pfizer (PFE) do?

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

NRIX vs PFE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • NRIX drivers: Bexobrutideg registrational path; Roche collaboration.
  • PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

NRIX or PFE: which should you pick?

If the story you believe is NRIX's (Bexobrutideg registrational path), NRIX is the more direct way to own it; if it is PFE's (Oncology expansion via Seagen), PFE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NRIX and PFE guides.

NRIX vs PFE: the full fundamentals

NRIX. Nurix's trailing P/E of about 5x is an artifact of one quarter: the Roche upfront payment produced roughly $550 million of net income in the August 2026 quarter, and analysts expect losses to resume in fiscal 2027. The market still values it on pipeline potential, partnership economics, and cash runway. With about $1.1 billion of cash against a market value near $1.4 billion after the Sanofi-driven selloff, investors are now assigning only about $0.3 billion to bexobrutideg and the rest of the pipeline, which is funded into the second half of 2029; dilution risk has eased while clinical risk remains. The 14 analysts Yahoo Finance tracks carry a mean target near $33.50, though several were set before the Sanofi news.

PFE. At about $27.54 (November 20, 2026) Pfizer trades at about 9x forward earnings with a dividend yield near 6.3%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges, including a GAAP loss in Q2 2026, rather than weak operations. After pulling back from its early-November high the stock sits below the 26 analysts' mean target of about $30.22 (an average buy rating), so the valuation balances substantial cash generation against flat-to-lower consensus earnings.

Headline figures (approximate, November 2026): NRIX shows revenue (q3 fy2026, quarter ended aug 31 2026) ~$673.1 million (~$653.2 million Roche license revenue), net income (q3 fy2026) ~$549.8 million (~$4.73 per share vs ~$5.02 consensus), revenue (ttm) ~$702 million, net income (ttm) ~$295 million; PFE shows revenue (ttm) ~$63.6 billion (Q3 2026 ~flat YoY), operating margin ~29%, net income (ttm, gaap) ~$4.0 billion, q3 2026 adjusted eps ~$0.87 vs ~$0.74 consensus.

The bottom line: NRIX vs PFE

NRIX and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NRIX and PFE exposure against your real portfolio. It is not an investment adviser.

Wondering how NRIX or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Nurix Therapeutics

Ask Walnut's AI anything about NRIX and see how it fits what you own.

FAQ

What is the difference between NRIX and PFE?

+

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NRIX or PFE the better stock?

+

Neither is universally better. PFE is the larger incumbent; NRIX is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NRIX or PFE?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NRIX and PFE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NRIX vs PFE?

+

NRIX: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The roughly $1.1 billion cash position eases near-term funding pressure. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected registrational path could sharply reduce the valuation. Partner risk is real, as November 2026 showed: Sanofi's decision to end SAR448272 cut about $455 million of potential milestones and sent the shares down about 38% in a day, and Wells Fargo said it had attributed about $400 million of value to the program. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and remaining milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of November 2026 has revenue of about $63.1 billion in 2026 slipping to $60.8 billion in 2027, with EPS of roughly $3.05 and $2.95, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.4 billion against $14.3 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout near 246% of trailing GAAP EPS of about $0.70), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NRIX or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.